Stefan Narváez-Labuhn

Stefan Narváez-Labuhn

Auto-generated profile, based on publicly available information

Stefan Narváez-Labuhn

AlergiaMx, Allergy & Clinical Immunology, Benito Juarez, CDMX 03810, Mexico

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025
Verified
Journal Article
Open access
PDF file
LHLuis Angel Hernández-Zárate
Luis Angel Hernández-Zárate
CGCarlos Andrés Gómez-Núñez
Carlos Andrés Gómez-Núñez
SNStefan Narváez-Labuhn
Stefan Narváez-Labuhn
GMGerardo Morales-Velázquez
Gerardo Morales-Velázquez
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder affecting millions worldwide, with significant variations in clinical presentation influenced by socioeconomic, racial, and environmental factors. This review explores the current understanding of AD pathophysiology, emphasizing immune dysregulation, epithelial barrier dysfunction, and the role of cytokines, particularly interleukin (IL)-4 and IL-13, in disease progression. Safety and efficacy concerns limit traditional corticosteroids, phototherapy, and systemic immunosuppressants, prompting interest in innovative therapies. New biologic agents, including monoclonal antibodies (mAbs) and Janus kinase (JAK) inhibitors (JAKis), target specific immune pathways, promising outcomes in moderate-to-severe AD cases. Biologics like dupilumab and emerging JAKis have shown substantial efficacy and safety in clinical trials, with notable reductions in inflammation and pruritus. However, these advancements present challenges, including hypersensitivity risks and the high costs of biologics, underscoring the need for further research on long-term safety and accessibility. The shift toward precision medicine in AD management marks a significant evolution, with future approaches likely to integrate targeted therapies alongside multidisciplinary care to enhance patient outcomes and quality of life (QoL).